Stifel Nicolaus Reiterates “Buy” Rating for Cooper Companies (COO)
Stifel Nicolaus reissued their buy rating on shares of Cooper Companies (NYSE:COO) in a report issued on Friday, MarketBeat Ratings reports. Stifel Nicolaus currently has a $265.00 price target on the medical device company’s stock, down from their prior price target of $275.00.
COO has been the subject of several other reports. Jefferies Group reissued a buy rating and set a $250.00 price objective on shares of Cooper Companies in a report on Tuesday, September 12th. Stephens reissued an equal weight rating and set a $250.00 price objective (up from $235.00) on shares of Cooper Companies in a report on Tuesday, September 12th. Zacks Investment Research raised Cooper Companies from a hold rating to a buy rating and set a $265.00 price objective for the company in a report on Tuesday, October 10th. KeyCorp reissued a hold rating on shares of Cooper Companies in a report on Monday, August 28th. Finally, Piper Jaffray Companies increased their price objective on Cooper Companies from $265.00 to $280.00 and gave the company an overweight rating in a report on Friday, September 1st. Six analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The company has an average rating of Buy and an average price target of $259.70.
Shares of Cooper Companies (COO) opened at $228.45 on Friday. The company has a current ratio of 2.41, a quick ratio of 1.26 and a debt-to-equity ratio of 0.36. The company has a market capitalization of $11,110.00, a P/E ratio of 23.31, a P/E/G ratio of 1.83 and a beta of 0.54. Cooper Companies has a 52-week low of $169.39 and a 52-week high of $256.39.
Cooper Companies (NYSE:COO) last issued its quarterly earnings results on Thursday, December 7th. The medical device company reported $2.65 EPS for the quarter, beating the Zacks’ consensus estimate of $2.64 by $0.01. Cooper Companies had a return on equity of 16.02% and a net margin of 17.43%. The company had revenue of $561.50 million during the quarter, compared to the consensus estimate of $558.86 million. During the same period last year, the business posted $2.28 earnings per share. Cooper Companies’s revenue was up 8.3% on a year-over-year basis. research analysts anticipate that Cooper Companies will post 11.54 EPS for the current fiscal year.
In other news, Director Gary S. Petersmeyer sold 3,977 shares of the firm’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $244.94, for a total value of $974,126.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 1.60% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the stock. Advisory Services Network LLC raised its position in shares of Cooper Companies by 30.6% in the second quarter. Advisory Services Network LLC now owns 457 shares of the medical device company’s stock worth $109,000 after buying an additional 107 shares in the last quarter. YorkBridge Wealth Partners LLC raised its position in shares of Cooper Companies by 2.1% in the second quarter. YorkBridge Wealth Partners LLC now owns 531 shares of the medical device company’s stock worth $126,000 after buying an additional 11 shares in the last quarter. Acrospire Investment Management LLC raised its position in shares of Cooper Companies by 50.0% in the second quarter. Acrospire Investment Management LLC now owns 600 shares of the medical device company’s stock worth $144,000 after buying an additional 200 shares in the last quarter. Canada Pension Plan Investment Board purchased a new stake in Cooper Companies during the third quarter valued at about $163,000. Finally, Penserra Capital Management LLC raised its position in Cooper Companies by 13.0% during the second quarter. Penserra Capital Management LLC now owns 884 shares of the medical device company’s stock valued at $211,000 after purchasing an additional 102 shares in the last quarter. Institutional investors own 96.79% of the company’s stock.
About Cooper Companies
The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.
Receive News & Ratings for Cooper Companies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc and related companies with MarketBeat.com's FREE daily email newsletter.